NLS Pharmaceutics and Kadimastem merge to form NewcelX

Reuters

2025/11/04

NLS Pharmaceutics and Kadimastem merge to form NewcelX

NLS Pharmaceutics Ltd. and Kadimastem Ltd. have completed a merger to form NewcelX Ltd., a Swiss clinical-stage biopharmaceutical company. The newly combined company brings together Kadimastem's advanced cell-therapy platforms with NLS's expertise in neuroscience and small-molecule drug development, aiming to create innovative treatments for neurodegenerative and metabolic diseases. In connection with the merger, the companies raised approximately $9 million through equity financing and warrant exercises, with additional financial support from a $25 million Equity Line of Credit facility. NewcelX has outlined plans for multiple clinical milestones over the next year, including a Phase 2a clinical study in ALS and expansion of its therapeutic pipeline. The update was disclosed by NewcelX Ltd.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NLS Pharmaceutics Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: LN14973) on November 04, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2580735331"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2580735331\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2580735331?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-04 20:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2580735331","market":"nz","top_or_hot":-1,"title":"NLS Pharmaceutics and Kadimastem merge to form NewcelX","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      NLS Pharmaceutics and Kadimastem merge to form NewcelX\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/NLSP\">NLS Pharmaceutics Ltd.</a> and Kadimastem Ltd. have completed a merger to form <a href=\"https://laohu8.com/S/NCEL\">NewcelX Ltd.</a>, a Swiss clinical-stage biopharmaceutical company. The newly combined company brings together Kadimastem's advanced cell-therapy platforms with NLS's expertise in neuroscience and small-molecule drug development, aiming to create innovative treatments for neurodegenerative and metabolic diseases. In connection with the merger, the companies raised approximately $9 million through equity financing and warrant exercises, with additional financial support from a $25 million Equity Line of Credit facility. NewcelX has outlined plans for multiple clinical milestones over the next year, including a Phase 2a clinical study in ALS and expansion of its therapeutic pipeline. The update was disclosed by NewcelX Ltd.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NLS Pharmaceutics Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: LN14973) on November 04, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>NLS Pharmaceutics and Kadimastem merge to form NewcelX</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNLS Pharmaceutics and Kadimastem merge to form NewcelX\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-04 20:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      NLS Pharmaceutics and Kadimastem merge to form NewcelX\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/NLSP\">NLS Pharmaceutics Ltd.</a> and Kadimastem Ltd. have completed a merger to form <a href=\"https://laohu8.com/S/NCEL\">NewcelX Ltd.</a>, a Swiss clinical-stage biopharmaceutical company. The newly combined company brings together Kadimastem's advanced cell-therapy platforms with NLS's expertise in neuroscience and small-molecule drug development, aiming to create innovative treatments for neurodegenerative and metabolic diseases. In connection with the merger, the companies raised approximately $9 million through equity financing and warrant exercises, with additional financial support from a $25 million Equity Line of Credit facility. NewcelX has outlined plans for multiple clinical milestones over the next year, including a Phase 2a clinical study in ALS and expansion of its therapeutic pipeline. The update was disclosed by NewcelX Ltd.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NLS Pharmaceutics Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: LN14973) on November 04, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251104:nNDL2kcDjF:1","article_id":"2580735331","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2580735331","pubTimestamp":1762257807,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"NLS Pharmaceutics Ltd. and Kadimastem Ltd. have completed a merger to form NewcelX Ltd., a Swiss clinical-stage biopharmaceutical company. The newly combined company brings together Kadimastem's advanced cell-therapy platforms with NLS's expertise in neuroscience and small-molecule drug development, aiming to create innovative treatments for neurodegenerative and metabolic diseases. In connection with the merger, the companies raised approximately $9 million through equity financing and warrant exercises, with additional financial support from a $25 million Equity Line of Credit facility. NewcelX has outlined plans for multiple clinical milestones over the next year, including a Phase 2a clinical study in ALS and expansion of its therapeutic pipeline. The update was disclosed by NewcelX Ltd.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","BK4007":"制药","NLSP":"NLS Pharmaceutics Ltd.","NCEL":"NewcelX Ltd."},"translate_title":"NLS Pharmaceutics与Kadimastem合并成立NewcelX","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NCEL":0.9,"NLSP":0.9},"content_text":"NLS Pharmaceutics and Kadimastem merge to form NewcelX\n    \n\nNLS Pharmaceutics Ltd. and Kadimastem Ltd. have completed a merger to form NewcelX Ltd., a Swiss clinical-stage biopharmaceutical company. The newly combined company brings together Kadimastem's advanced cell-therapy platforms with NLS's expertise in neuroscience and small-molecule drug development, aiming to create innovative treatments for neurodegenerative and metabolic diseases. In connection with the merger, the companies raised approximately $9 million through equity financing and warrant exercises, with additional financial support from a $25 million Equity Line of Credit facility. NewcelX has outlined plans for multiple clinical milestones over the next year, including a Phase 2a clinical study in ALS and expansion of its therapeutic pipeline. The update was disclosed by NewcelX Ltd.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NLS Pharmaceutics Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: LN14973) on November 04, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation,merge","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}